ReviewFrontiers in medicine2017
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma.
Review in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review.Frontiers in medicine · 2026Pooled it
- Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Pooled it
- Emerging perspectives in respiratory allergic diseases: a review of future directions.Frontiers in allergy · 2026Review
- IL-5 signaling in asthmatic derived fibroblasts exacerbates airway remodeling through ECM dysregulation and apoptosis resistance.Respiratory research · 2025Article
- Tartaric Acid Exacerbates DSS-Induced Colitis by Promoting Eosinophilic Inflammation via IL-13 and IL-5Rα Upregulation.Pathogens (Basel, Switzerland) · 2025Article
- Monoclonal antibodies in severe asthma: outcomes from real-world data.Frontiers in medicine · 2025Article
- Review
- Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.American journal of clinical dermatology · 2024Review
- Gender dimorphism in IgA subclasses in T2-high asthma.Clinical and experimental medicine · 2023Article
- Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting.Journal of clinical medicine · 2023Article
- The Role of Benralizumab in Eosinophilic Immune Dysfunctions: A Case Report-Based Literature Review.Case reports in medicine · 2023Article
- Human Lung Mast Cells: Therapeutic Implications in Asthma.International journal of molecular sciences · 2022Review
- Off-Label Benralizumab in Severe Non-Necrotizing Eosinophilic Vasculitis following Critical COVID-19 Disease and in DRESS.Journal of clinical medicine · 2022Article
- The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps.International forum of allergy & rhinology · 2022Review
- Neutrophil extracellular traps and neutrophil-derived mediators as possible biomarkers in bronchial asthma.Clinical and experimental medicine · 2022Article
- Bullous pemphigoid-What do we know about the most recent therapies?Frontiers in medicine · 2022Review
- The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions.Current research in immunology · 2022Review
- A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions.Annals of medicine and surgery (2012) · 2021Article
- Review
- Treatable Mechanisms in Asthma.Molecular diagnosis & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The definition of asthma has changed considerably in recent years, to the extent that asthma is no longer considered a single disease but a heterogeneous disorder that includes several phenotypes and, possibly, endotypes. A more detailed analysis of the immunological mechanisms underlying the pathogenesis of asthma shows interleukin 5 (IL-5) to be a crucial cytokine in several asthma phenotypes. In fact, IL-5 exerts selective action on eosinophils, which, in turn, sustain airway inflammation and worsen asthma symptoms and control. Clinical trials have shown drugs targeting IL-5 or its receptor alpha subunit (IL-5Ra) to be a promising therapeutic approach to severe asthma, whose characteristics render standard therapy of little use: systemic corticosteroids only partially control the disease and have well-known adverse effects, and omalizumab is used for allergic subtypes. Analysis of the design process of clinical trials reveals the importance of patient selection, taking into account both clinical data (e.g., exacerbations, lung function, and quality of life) and biomarkers (e.g., eosinophils, which are predictive of therapeutic response).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.